Nuvation Bio Inc. shareholders approved To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. at the 2026-05-21 meeting.
“Proposal No. 3 - To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.”
Shareholder Votes
Nuvation Bio Inc. shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2026-05-21 meeting.
“Proposal No. 2 - Ratification of Independent Registered Public Accounting Firm. The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Shareholder Votes
Nuvation Bio Inc. shareholders approved Election of Directors at the 2026-05-21 meeting.
“Proposal No. 1 - Election of Directors. The individuals listed below were elected at the Annual Meeting to serve as directors of the Company until the Company’s 2029 annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal.”
Earnings Releases
Nuvation Bio Inc. reported first quarter ended March 31, 2026 results: revenue $18.5 million.
“Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI”
Material Agreements
Nuvation Bio Inc. entered into License Agreement with Eisai Co., Ltd. valued at €50 million (effective 2026-01-11).
“On January 11, 2026, Nuvation Bio Inc. (the “Company”) entered into a License and Collaboration Agreement (the “License Agreement”) with Eisai Co., Ltd. (“Eisai”).”
Debt Financings
Nuvation Bio Inc. incurred debt of $150 million with Sagard Healthcare Partners (Delaware) II LP.
“On the Closing Date, the Company also entered into a Revenue Interest Financing Agreement (the “Financing Agreement”) with Sagard Healthcare Partners (Delaware) II LP (the “Investor”), pursuant to which the Investor has agreed to pay the Company $150 million (the “Investment Amount”) to provide funding for the Company’s development and commercialization of taletrectinib upon receipt of FDA Approval (as defined in the Financing Agreement) of taletrectinib.”
Debt Financings
Nuvation Bio Inc. incurred loan of $100.0 million with Sagard Holdings Manager LP at secured overnight financing rate (subject to a 4.00% floor) plus a margin of 6.0 maturing September 30, 2030.
“On March 3, 2025 (the “Closing Date”), Nuvation Bio Inc. (the “Company”) entered into a $100.0 million senior secured loan agreement (the “Loan Agreement”), with Sagard Holdings Manager LP (“Sagard”) as administrative agent, and the lenders party thereto.”
Jerry Wang resigned as Member of the Board of Directors at Nuvation Bio Inc..
“Additionally, on February 11, 2025, Dr. Wang notified the board of directors (the “Board”) of his resignation as a member of the Board, effective February 11, 2025.”
Jerry Wang departed as Chief Executive Officer of AnHeart Therapeutics at Nuvation Bio Inc..
“On February 12, 2025, Dr. Jerry Wang, the Chief Executive Officer of AnHeart Therapeutics, a Nuvation Bio Inc. (the “Company”) company, departed the Company following the achievement of key Company goals”
Philippe Sauvage was appointed as Chief Financial Officer at Nuvation Bio Inc..
“Effective October 7, 2024 (the “Appointment Date”), the Board of Nuvation Bio Inc. (the “Company”) appointed Philippe Sauvage as the Company’s Chief Financial Officer and Principal Financial Officer.”
Earnings Releases
Nuvation Bio Inc. reported the first quarter ended March 31, 2024 results: net income $14.8 million, EPS $(0.07) per share.
“For the three months ended March 31, 2024, Nuvation Bio reported a net loss of $14.8 million, or $(0.07) per share.”
Governance Changes
Nuvation Bio Inc.: Filed Certificate of Designation for Series A Non-Voting Convertible Preferred Stock in connection with the Acquisition (effective 2024-04-09).
“On April 9, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware in connection with the closing of the Acquisition.”
M&A Transactions
Nuvation Bio Inc. completed an acquisition involving AnHeart Therapeutics, Ltd. (closed 2024-04-09).
“On April 9, 2024, the Company completed its previously announced acquisition (the “Acquisition”) of AnHeart Therapeutics, Ltd.”
Material Agreements
Nuvation Bio Inc. entered into Warrant Agreement with Continental Stock Transfer & Trust Company (effective 2024-04-09).
“On April 9, 2024, in connection with the Acquisition (as defined below), Nuvation Bio Inc. (the “Company”) entered into the amended and restated warrant agreement (the “Warrant Agreement”) with Continental Stock Transfer & Trust Company, as warrant agent”
Xiangmin (Min) Cui was appointed as Director at Nuvation Bio Inc..
“Dr. Junyuan (Jerry) Wang and Dr. Xiangmin (Min) Cui, Ph.D. were appointed as Class I and Class III directors, respectively, to the Company’s board of the directors (the “Board”).”
Junyuan (Jerry) Wang was appointed as Director at Nuvation Bio Inc..
“Dr. Junyuan (Jerry) Wang and Dr. Xiangmin (Min) Cui, Ph.D. were appointed as Class I and Class III directors, respectively, to the Company’s board of the directors (the “Board”).”
Material Agreements
Nuvation Bio Inc. entered into Agreement and Plan of Merger and Reorganization with AnHeart Therapeutics Ltd. (effective 2024-03-24).
“On March 24, 2024, Nuvation Bio Inc., a Delaware corporation (“Nuvation Bio” or the “Company”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with AnHeart Therapeutics Ltd., an exempted company incorporated under the laws of the Cayman Islands (“AnHeart"), Artemis Merger Sub I, Ltd., an exempted company incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of the Company (“Merger Sub I”), and Artemis Merger Sub II, Ltd., an exempted company incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of the Company (“Merger Sub II”).”
Earnings Releases
Nuvation Bio Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income net loss of $13.8 million, or $(0.06) per share, EPS $(0.06) per share.
“Nuvation Bio reported a net loss of $13.8 million, or $(0.06) per share.”
Robert Mashal was appointed as Director at Nuvation Bio Inc..
“On January 8, 2024 the Board of Directors (the “ Board ”) of Nuvation Bio Inc. (the “ Company ”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Robert Mashal, M.D. to fill a vacant Board seat and to serve as a Class II director, with an initial term expiring at the Company’s 2026 Annual Meeting of Stockholders.”
Oleg Nodelman resigned as Director at Nuvation Bio Inc..
“On December 11, 2023, Oleg Nodelman notified Nuvation Bio Inc. (the “Company”) of his intent to resign as a member of the Company’s Board of Directors (the “Board”), and he subsequently delivered a letter to the Board on December 12, 2023 documenting his resignation effective immediately.”
Moses Makunje was appointed as Principal Accounting Officer and Principal Financial Officer at Nuvation Bio Inc..
“Effective November 27, 2023, the Board of Nuvation Bio Inc. (the “Company”) appointed Moses Makunje as the Company’s Principal Accounting Officer and Principal Financial Officer.”
Jennifer Fox resigned as Chief Financial Officer at Nuvation Bio Inc..
“On November 9, 2023, Jennifer Fox, the Chief Financial Officer of Nuvation Bio Inc. (the “Company”), notified the Company of her decision to pursue a new opportunity and resign from her position at the Company effective November 27, 2023.”
Earnings Releases
Nuvation Bio Inc. reported the third quarter ended September 30, 2023 results: net income net loss of $19.6 million, or $(0.09) per share, EPS $(0.09) per share.
“Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023”
Shareholder Votes
Nuvation Bio Inc. shareholders approved Advisory vote on executive compensation at the 2023-05-15 meeting.
“Proposal No. 3 – To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. FOR AGAINST ABSTAIN BROKER NON-VOTE 153,714,329 38,025,124 9,887 14,982,485”
Shareholder Votes
Nuvation Bio Inc. shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2023-05-15 meeting.
“The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. FOR AGAINST ABSTAIN BROKER NON-VOTE 206,334,068 118,931 278,826 0”
Shareholder Votes
Nuvation Bio Inc. shareholders approved Election of Directors at the 2023-05-15 meeting.
“The individuals listed below were elected at the Annual Meeting to serve as directors of the Company until the Company’s 2026 annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal. CLASS A STOCK DIRECTORS: FOR WITHHELD BROKER NON-VOTE Mr. Robert B. Bazemore, Jr. 140,642,378 50,106,962 14,982,485 CLASS B STOCK DIRECTORS: FOR WITHHELD BROKER NON-VOTE Kim Blickenstaff 1,000,000 0 0”
Earnings Releases
Nuvation Bio Inc. reported the first quarter ended March 31, 2023 results: net income $21.7 million, EPS $(0.10) per share.
“For the three months ended March 31, 2023, Nuvation Bio reported a net loss of $21.7 million, or $(0.10) per share.”
Earnings Releases
Nuvation Bio Inc. reported the fourth quarter and full year ended December 31, 2022 results: net income a net loss of $20.8 million, or $(0.10) per share, EPS $(0.10) per share.
“On March 15, 2023, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended December 31, 2022.”
Earnings Releases
Nuvation Bio Inc. reported the third quarter ended September 30, 2022 results: net income net loss of $27.2 million, or $(0.12) per share, EPS $(0.12) per share.
“For the three months ended September 30, 2022, Nuvation Bio reported a net loss of $27.2 million, or $(0.12) per share.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.